 |
Talking Biotech with Dr. Kevin FoltaTalking Biotech is a weekly podcast that uncovers the stories, ideas and research of people at the frontier of biology and engineering. Author: Colabra
Talking Biotech is a weekly podcast that uncovers the stories, ideas and research of people at the frontier of biology and engineering. Each episode explores how science and technology will transform agriculture, protect the environment, and feed 10 billion people by 2050. Interviews are led by Dr. Kevin Folta, a professor of molecular biology and genomics. Language: en-us Genres: Life Sciences, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
A Plasmid-Based Cancer Therapy - Dr. Alexander Schneider
Episode 488
Monday, 16 February, 2026
In this episode of the Talking Biotech podcast, host Dr. Kevin Folta engages with Dr. Alex Schneider, CEO and founder of CureLab, to discuss innovative approaches to cancer treatment, particularly focusing on the challenges posed by refractory cancers such as triple-negative breast cancer and platinum-resistant ovarian cancer. Dr. Schneider emphasizes the evolution of cancer therapies from traditional chemotherapy to more sophisticated immunotherapies, highlighting the importance of understanding immune responses in combating cancer. He introduces Elanogen, a plasmid-based therapy designed to enhance immune presentation and combat chronic inflammation, which can hinder the effectiveness of conventional treatments like gemcitabine.The conversation delves into the mechanisms of Elanogen, explaining how it targets the P62 protein, which is overproduced in cancer cells, making them vulnerable to immune attacks. Dr. Schneider shares insights from clinical trials, noting the promising results of combining Elanogen with standard chemotherapy, and discusses future applications of this therapy in various cancers and even non-cancerous diseases associated with chronic inflammation. The episode concludes with a call for intellectual humility in science, as both hosts reflect on the evolving nature of cancer research and the potential for new discoveries in the field.
